McDermott Will & Emery
Subscribe to McDermott Will & Emery's Posts
By McDermott Will & Emery on Jul 3, 2019
Posted In Digital Health, FDA, Life Sciences, Life Sciences Private Equity, Reimbursement
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a result, may pay less attention to issues such as supply chain, intellectual property components and...
By McDermott Will & Emery on Feb 19, 2019
Posted In Health M&A, Health Private Equity, Hospitals & Health Systems, Managed Care, Transition to Transformation
We greatly appreciate our readers continuing to turn to us for insight on the most critical legal, regulatory and transactional developments, and innovative collaborations transforming health care. Over the past year, McDermott’s Health practice made headlines for our work on several of the most high-profile collaborative transformations that took place in 2018: We were one...
By McDermott Will & Emery and Nicholas Alarif on Jun 14, 2018
Posted In Fraud & Abuse, Health Controversies, Managed Care
Providers continue to face a massive Medicare appeals backlog before the Office of Medicare Hearing and Appeals (OMHA). Pending appeals number in the hundreds of thousands and the current average processing time for an appeal is over three years, with newly filed appeals likely to reach closer to five. While OMHA and Medicare reimbursement appeals...
By McDermott Will & Emery on May 31, 2018
Posted In Digital Health, FDA, Life Sciences
McDermott is gearing up for an exciting week of programming during the 2018 BIO International Convention. A number of McDermott partners will on the ground as panelists and moderators across a range of programs during BIO and we hope to see you there! Thursday, May 31 | Al Sokol will moderate a panel discussion on...
By McDermott Will & Emery and Karen Owen Gibbs on Apr 10, 2018
Posted In FDA, Health M&A, Health Private Equity, Hospitals & Health Systems, Life Sciences, PPM/ASC
Specialty pharmacy is not going away any time soon – by 2020, it’s expected that the pharmacy industry’s revenue will exceed $483 billion, with almost all growth as a result of specialty drugs (high-cost medications used to treat chronic conditions, such as cancer). It’s also estimated that the next generation of pharmaceutical “blockbusters” will be...